<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Gormsen | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/heatshark0/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/heatshark0/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Gormsen.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">173d33dba31fb7d0d652e328cb633703</guid>
				<title>Gormsen posted an update: In conclusion, we report for the first time that a specific [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42852/</link>
				<pubDate>Sun, 09 Feb 2025 11:43:06 -0800</pubDate>

									<content:encoded><![CDATA[<p>In conclusion, we report for the first time that a specific strain of LA causes a strain-specific enhancement of intestinal TJ barrier through a novel mechanism that involves the TLR-2 receptor complex and protects against the DSS-induced colitis by targeting the intestinal TJ barrier.Loss-of-function mutations in arachidonate lipoxygenase 12B&hellip;<span class="activity-read-more" id="activity-read-more-42852"><a href="http://www.nationalboardinstitute.com/activity/p/42852/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">5e232d95eb0921b7efe42c7c07b7087d</guid>
				<title>Gormsen posted an update: The interventions of this protocol have been programmed to [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41959/</link>
				<pubDate>Sat, 08 Feb 2025 11:41:27 -0800</pubDate>

									<content:encoded><![CDATA[<p>The interventions of this protocol have been programmed to alleviate constipation in patients with neurogenic bowel dysfunction. Findings may provide preliminary evidence for clinical efficacy of the therapy of &#8220;combination 3 methods progression.&#8221;</p>
<p> Chinese Clinical Trial Registry, IDF ChiCTR2000041463. Registered on December 26,&hellip;<span class="activity-read-more" id="activity-read-more-41959"><a href="http://www.nationalboardinstitute.com/activity/p/41959/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">005cdea6183a5c3c7bd9e80ac1472109</guid>
				<title>Gormsen posted an update: Autism spectrum disorder (ASD) and epilepsy are highly [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40064/</link>
				<pubDate>Thu, 06 Feb 2025 12:45:22 -0800</pubDate>

									<content:encoded><![CDATA[<p>Autism spectrum disorder (ASD) and epilepsy are highly comorbid, suggesting potential overlap in genetic etiology, pathophysiology, and neurodevelopmental abnormalities; however, the nature of this relationship remains unclear. This work investigated how two ion channel mutations, one associated with autism (Scn2a-null) and one with epilepsy&hellip;<span class="activity-read-more" id="activity-read-more-40064"><a href="http://www.nationalboardinstitute.com/activity/p/40064/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4fed95920423d56abbc88c24fb7ba0c6</guid>
				<title>Gormsen posted an update: escribing practices do not view DPs and POC-CRPT as [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38450/</link>
				<pubDate>Tue, 04 Feb 2025 11:36:18 -0800</pubDate>

									<content:encoded><![CDATA[<p>escribing practices do not view DPs and POC-CRPT as sufficiently useful &#8216;clinical tools&#8217; in a way which corresponds to the current policy approach advocating their use to reduce clinical uncertainty and improve antimicrobial stewardship. Instead, policy attention should focus on how these strategies may instead be used as &#8216;social tools&#8217; to reduce&hellip;<span class="activity-read-more" id="activity-read-more-38450"><a href="http://www.nationalboardinstitute.com/activity/p/38450/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7b2f21ed4ee4c5693927d2990082b16e</guid>
				<title>Gormsen posted an update: Hepatitis B virus (HBV) vaccination rates are insufficient [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35837/</link>
				<pubDate>Sat, 01 Feb 2025 11:34:57 -0800</pubDate>

									<content:encoded><![CDATA[<p>Hepatitis B virus (HBV) vaccination rates are insufficient in high-risk patients worldwide. This study aimed to investigate the screening, immunization, and vaccination rates in three high-risk groups for HBV infection allogeneic hematopoietic stem cell transplantation (AHSCT), renal transplantation (RT), and chronic hepatitis C (CHC)&hellip;<span class="activity-read-more" id="activity-read-more-35837"><a href="http://www.nationalboardinstitute.com/activity/p/35837/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">66d6c4ac6794cfd40422cb45e8259bf7</guid>
				<title>Gormsen posted an update: It is necessary to fully answer the question of what [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34012/</link>
				<pubDate>Thu, 30 Jan 2025 11:35:59 -0800</pubDate>

									<content:encoded><![CDATA[<p>It is necessary to fully answer the question of what initiators and metabolic imbalances are particularly important, considering sterile inflammation as the architect of the disease. Due to the shortage of elucidation of NASH progression, we discuss in this review, how inflammation is a key part of this development and we presume the targets&hellip;<span class="activity-read-more" id="activity-read-more-34012"><a href="http://www.nationalboardinstitute.com/activity/p/34012/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7b6863c362fdaf1719313aaf05b9748c</guid>
				<title>Gormsen posted an update: The upregulation of CD11b implies that NET causes [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29493/</link>
				<pubDate>Tue, 28 Jan 2025 13:13:25 -0800</pubDate>

									<content:encoded><![CDATA[<p>The upregulation of CD11b implies that NET causes neutrophils to more actively contribute to inflammation. The increased oxidative burst capacity of neutrophils can play a double role in inflammation. Overall, the effects induced by NET on neutrophils help prolong inflammation; accordingly, the NET collected from SLE patients is stronger than the&hellip;<span class="activity-read-more" id="activity-read-more-29493"><a href="http://www.nationalboardinstitute.com/activity/p/29493/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1ce85beca675d134ea9fe23f566df4ff</guid>
				<title>Gormsen became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29417/</link>
				<pubDate>Tue, 28 Jan 2025 13:08:36 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>